GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Clinical Trials
726
Trial Phases
5 Phases
Drug Approvals
2
Clinical Trials
Distribution across different clinical trial phases (678 trials with phase data)• Click on a phase to view related trials
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
- Conditions
- HIV-1-infection
- Interventions
- Drug: B/F/TAF
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 16
- Registration Number
- NCT07055451
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
- Conditions
- HIV Pre-exposure Prophylaxis
- Interventions
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 300
- Registration Number
- NCT07047716
Study of GS-3242 in Participants With HIV-1
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT07001319
- Locations
- 🇺🇸
Quest Clinical Research,Substudy-05, San Francisco, California, United States
🇺🇸Washington Health Institute,Substudy-05, Washington, District of Columbia, United States
🇺🇸Midland Florida Clinical Research Center, LLC,Substudy-05, DeLand, Florida, United States
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: Sacituzumab Govitecan-hziy (SG)
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT06926920
- Locations
- 🇺🇸
Los Angeles Cancer Network (LACN) - Good Sam, Los Angeles, California, United States
Study of GS-0151 in Participants With Rheumatoid Arthritis
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 75
- Registration Number
- NCT06902519
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸Clinical Research of West Florida, Inc, Clearwater, Florida, United States
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 132
- Next
News
Arcus Biosciences' CD73 Inhibitor Quemliclustat Receives FDA Orphan Drug Designation for Pancreatic Cancer
Arcus Biosciences announced that quemliclustat, an investigational small-molecule CD73 inhibitor, received FDA orphan drug designation for treating pancreatic cancer.
Assembly Biosciences Initiates Phase 1b Trial of Long-Acting HSV Helicase-Primase Inhibitor ABI-1179
Assembly Biosciences has dosed the first participant in the Phase 1b portion of its clinical trial evaluating ABI-1179, a long-acting herpes simplex virus helicase-primase inhibitor for recurrent genital herpes.
FDA Maintains Record-Breaking Approval Pace Despite Organizational Upheaval, Highlighting Three Breakthrough Therapies
The FDA has approved 84 drugs in 2025 so far, marking the second-highest total for this period despite major organizational changes including 3,500 staff layoffs.
Assembly Biosciences' ABI-4334 Shows Potent Antiviral Activity in Phase 1b Chronic Hepatitis B Trial
Assembly Biosciences reported positive Phase 1b results for ABI-4334, a next-generation capsid assembly modulator, showing potent antiviral activity against chronic hepatitis B virus infection.
FDA Approves Lenacapavir for HIV Prevention with 99.9% Efficacy, but High Cost Raises Accessibility Concerns in India
The US FDA has approved lenacapavir, a new injectable HIV prevention drug offering 99.9% protection against HIV infection.
BioNTech Shuts Down Maryland Cell Therapy Manufacturing Following CAR-T Trial Failure
BioNTech will lay off 63 employees and wind down cell therapy manufacturing at its Gaithersburg, Maryland facility by the end of 2025 following disappointing Phase 1 trial results.
Comprehensive Analysis Reveals 943 Autoimmune Collaboration and Licensing Deals Across 30 Diseases from 2016-2025
A new comprehensive report analyzes 943 autoimmune collaboration and licensing deals from 2016-2025, covering over 30 diseases including multiple sclerosis, rheumatoid arthritis, lupus, and Crohn's disease.
FDA Places Clinical Hold on Gilead's Weekly HIV Combination Therapy Following Safety Signal
The FDA has placed a clinical hold on five Gilead HIV trials involving weekly combination therapy GS-1720 and GS-4182 after safety signals showed decreased CD4+ T-cell and lymphocyte counts in some patients.
Lenacapavir Shows 100% Efficacy in HIV Prevention with Twice-Yearly Injection
Lenacapavir, a novel capsid inhibitor, demonstrated 100% effectiveness in preventing HIV transmission in the PURPOSE clinical trials, surpassing existing PrEP options.
Protara Therapeutics Appoints William Conkling as Chief Commercial Officer to Lead Commercialization Strategy
Protara Therapeutics has appointed William Conkling as Chief Commercial Officer, bringing over two decades of experience in developing and commercializing cancer and rare disease therapeutics.